Description_x000D_ General description_x000D_ MARK4 contains an N-terminal serine/threonine kinase domain, a central ubiquitin-associated domain, and a C-terminal KA1-associated kinase domain. RT-PCR analysis detects upregulated expression of the gene for MARK4 in nearly all clinical hepatocellular carcinoma cells. Northern blot analysis reveals ubiquitous expression of a 3.6-kb transcript, with highest expression in testis. Immunofluorescence microscopy demonstrates homogeneous cytoplasmic expression. Colony-forming assays show that MARK4 antisense reduces the growth of SNU475 cells. It has been suggested that MARK4 provides a growth advantage to cells._x000D_ Immunogen_x000D_ MARK4 (NP_11360, 15-45)_x000D_ This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human MARK4._x000D_ Application_x000D_ Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below._x000D_ Immunohistochemistry (1 paper)_x000D_ Physical form_x000D_ Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.